Sanofi Pasteur, A Sanofi Company

This study tested a new mRNA vaccine designed to protect against COVID-19 in 182 healthy adults aged 18 and older. The main goals were to check the vaccine's safety and measure the immune response it produced. The trial was stopped early, so results are limited, but it aimed to f…

This study tested a nasal spray vaccine to protect infants and toddlers (6 to 22 months old) from RSV, a common virus that can cause serious breathing problems. About 6300 healthy children were to receive either the vaccine or a placebo. The trial was terminated, so results are n…

This early-stage study tested a new meningococcal B vaccine in 576 healthy people, from infants to adults. The goal was to check safety and how well the vaccine triggers an immune response, comparing it to existing vaccines. The trial was terminated early, so results may be limit…

This study tested an experimental RSV vaccine given to healthy infants at 6 and 12 months old, along with their routine vaccines. The goal was to see if the RSV vaccine interfered with the body's ability to respond to the regular shots. The study was stopped early, so results are…

This study tested a respiratory syncytial virus (RSV) vaccine in healthy infants and toddlers aged 6 to 22 months. The goal was to see if a lower dose of the vaccine triggers a similar immune response as the standard dose, and to check the safety of different doses. The vaccine w…

This study tested whether a high-dose flu vaccine works better than the standard dose at preventing the flu in children aged 6 to 35 months. About 100 children took part. The study was stopped early, so results are limited.

This study compared a high-dose flu vaccine to a standard-dose one in over 33,000 adults aged 65 and older. The goal was to see if the stronger shot could better prevent hospital stays for heart or breathing problems. The study was stopped early, but the results help us understan…

This study tested a new recombinant flu vaccine against the standard egg-based flu shot in 366 children aged 3 to 8. The goal was to see if the new vaccine produced a similar or better immune response and was just as safe. The trial was stopped early, but the results help researc…